- Home
- TLPH vs GDO Comparison
TLPH vs GDO Comparison
Compare TLPH & GDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$1.19
Company Overview
Basic Information| Metric | TLPH | GDO |
|---|---|---|
| Founded | 2005 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.3M | 80.2M |
| IPO Year | 2010 | 2009 |
Fundamental Metrics
Financial Performance| Metric | TLPH | GDO |
|---|---|---|
| Price | $1.19 | $10.16 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 301.1K | 51.1K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,151,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.50 | $10.15 |
| 52 Week High | $1.57 | $12.15 |
Technical Indicators
Market Signals| Indicator | TLPH | GDO |
|---|---|---|
| Relative Strength Index (RSI) | 43.04 | 28.19 |
| Support Level | $0.74 | N/A |
| Resistance Level | $1.48 | $10.86 |
| Average True Range (ATR) | 0.08 | 0.05 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 21.79 | 2.38 |
Price Performance
Historical Comparison TLPH
GDO
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About GDO Western Asset Global Corporate Defined Opportunity Fund Inc.
Western Asset Global Corp Defined Opp is a closed-end management investment company with a primary investment objective to provide current income. Its secondary objective is to seek capital appreciation. The Fund invests in the United States and foreign corporate fixed-income securities of varying maturities.